![Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study - Gastroenterology Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d3018e26-bf9f-4dbf-8b5b-07990f6c8c6d/gr1.jpg)
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study - Gastroenterology
![Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler - ScienceDirect Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0378517315005050-fx1.jpg)
Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler - ScienceDirect
![These highlights do not include all the information needed to use budesonide inhalation suspension safely and effectively. See full prescribing information for budesonide inhalation suspension.BUDESONIDE inhalation suspension Initial U.S. Approval: 2000 These highlights do not include all the information needed to use budesonide inhalation suspension safely and effectively. See full prescribing information for budesonide inhalation suspension.BUDESONIDE inhalation suspension Initial U.S. Approval: 2000](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=NDC+68258-8922-05------TEVA.jpg&id=104851)
These highlights do not include all the information needed to use budesonide inhalation suspension safely and effectively. See full prescribing information for budesonide inhalation suspension.BUDESONIDE inhalation suspension Initial U.S. Approval: 2000
![Budesonide Capsules Market to 2027 – Perrigo, Mylan, Tillotts Pharma and Others – Press Releases-Read Business Intelligence Solution Budesonide Capsules Market to 2027 – Perrigo, Mylan, Tillotts Pharma and Others – Press Releases-Read Business Intelligence Solution](https://readbis.files.wordpress.com/2021/05/global-budesonide-capsules-market-share-by-companies.png?w=321)
Budesonide Capsules Market to 2027 – Perrigo, Mylan, Tillotts Pharma and Others – Press Releases-Read Business Intelligence Solution
![Fluticasone propionate/salmeterol AirDuo RespiClick Inhaler Teva Pharmaceutical Industries, Salmeterol, albuterol, skin Care png | PNGEgg Fluticasone propionate/salmeterol AirDuo RespiClick Inhaler Teva Pharmaceutical Industries, Salmeterol, albuterol, skin Care png | PNGEgg](https://e7.pngegg.com/pngimages/982/189/png-clipart-fluticasone-propionate-salmeterol-airduo-respiclick-inhaler-teva-pharmaceutical-industries-salmeterol-albuterol-skin-care.png)
Fluticasone propionate/salmeterol AirDuo RespiClick Inhaler Teva Pharmaceutical Industries, Salmeterol, albuterol, skin Care png | PNGEgg
![Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c8a53fd8-7246-40de-acd7-9d497f8dee0c/gr1_lrg.gif)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine
![Teva receives EU Marketing Authorisation for Seffalair® Spiromax® and BroPair® Spiromax® (salmeterol xinafoate / fluticasone propionate) | Business Wire Teva receives EU Marketing Authorisation for Seffalair® Spiromax® and BroPair® Spiromax® (salmeterol xinafoate / fluticasone propionate) | Business Wire](https://mms.businesswire.com/media/20210408005322/en/739014/22/teva_RGB_JPEG.jpg)